A Glimpse Into The Expert Outlook On Integra Lifesciences Through 8 Analysts
Portfolio Pulse from Benzinga Insights
Analyst ratings for Integra Lifesciences (NASDAQ:IART) show a mix of sentiments, with recent adjustments reflecting a bearish outlook. The average 12-month price target is now $33.5, down 23.2% from the previous $43.62. Analysts from firms like Morgan Stanley, JMP Securities, and Wells Fargo have lowered their price targets, indicating concerns over the company's market position and financial health. Despite a strong net margin and ROE, Integra faces challenges with negative revenue trends and a market capitalization below industry benchmarks.
May 07, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Integra Lifesciences faces a bearish outlook from analysts, with lowered price targets and concerns over its financial performance and market position.
The bearish sentiment from analysts, evidenced by lowered price targets and concerns over negative revenue trends and market capitalization, suggests a potential short-term negative impact on IART's stock price. The comprehensive analysis by multiple analysts from reputable firms further supports the likelihood of a downward trend, given the adjustments in ratings and price targets reflecting a cautious or negative outlook on the company's future performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100